BR112014012137A2 - anticorpos anti-fgfr2 e suas utilizações - Google Patents
anticorpos anti-fgfr2 e suas utilizaçõesInfo
- Publication number
- BR112014012137A2 BR112014012137A2 BR112014012137A BR112014012137A BR112014012137A2 BR 112014012137 A2 BR112014012137 A2 BR 112014012137A2 BR 112014012137 A BR112014012137 A BR 112014012137A BR 112014012137 A BR112014012137 A BR 112014012137A BR 112014012137 A2 BR112014012137 A2 BR 112014012137A2
- Authority
- BR
- Brazil
- Prior art keywords
- fgfr2 antibodies
- fgfr2
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11190227 | 2011-11-23 | ||
| PCT/EP2012/073325 WO2013076186A1 (en) | 2011-11-23 | 2012-11-22 | Anti-fgfr2 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014012137A2 true BR112014012137A2 (pt) | 2017-05-30 |
Family
ID=47278276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014012137A BR112014012137A2 (pt) | 2011-11-23 | 2012-11-22 | anticorpos anti-fgfr2 e suas utilizações |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20140322220A1 (pt) |
| EP (1) | EP2782934A1 (pt) |
| JP (1) | JP2015504434A (pt) |
| KR (1) | KR20140102698A (pt) |
| CN (1) | CN104066750B (pt) |
| AR (1) | AR088941A1 (pt) |
| AU (1) | AU2012342474A1 (pt) |
| BR (1) | BR112014012137A2 (pt) |
| CA (1) | CA2856325A1 (pt) |
| IL (1) | IL232399A0 (pt) |
| MX (1) | MX2014005855A (pt) |
| RU (1) | RU2014125143A (pt) |
| SG (2) | SG10201603880WA (pt) |
| WO (1) | WO2013076186A1 (pt) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013059740A1 (en) | 2011-10-21 | 2013-04-25 | Foundation Medicine, Inc. | Novel alk and ntrk1 fusion molecules and uses thereof |
| US20150023989A1 (en) * | 2011-12-14 | 2015-01-22 | Seattle Genetics, Inc. | New antibody drug conjugates (adcs) and the use thereof |
| CA2890207A1 (en) | 2012-11-05 | 2014-05-08 | Foundation Medicine, Inc. | Novel ntrk1 fusion molecules and uses thereof |
| AU2013337264B2 (en) | 2012-11-05 | 2018-03-08 | Foundation Medicine, Inc. | Novel fusion molecules and uses thereof |
| CA3150658A1 (en) * | 2013-01-18 | 2014-07-24 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
| EP4036118A1 (en) | 2013-08-01 | 2022-08-03 | Five Prime Therapeutics, Inc. | Afucosylated anti-fgfr2iiib antibodies |
| HUE053654T2 (hu) | 2014-03-26 | 2021-07-28 | Astex Therapeutics Ltd | FGFR- és CMET-inhibitorok kombinációi a rák kezelésére |
| US10780182B2 (en) | 2014-04-25 | 2020-09-22 | The Trustees Of The University Of Pennsylvania | Methods and compositions for treating metastatic breast cancer and other cancers in the brain |
| MA44179B1 (fr) | 2014-05-13 | 2020-10-28 | Univ Pennsylvania | Compositions comprenant un virus adeno-associe exprimant des constructions a double anticorps et leurs utilisations |
| SG11201702381QA (en) | 2014-09-26 | 2017-04-27 | Janssen Pharmaceutica Nv | Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| TW201642904A (zh) * | 2015-04-08 | 2016-12-16 | 第一三共股份有限公司 | 含抗ｆｇｆｒ２抗體及其他藥劑之組成物 |
| EP3287522A4 (en) * | 2015-04-20 | 2019-03-27 | Daiichi Sankyo Company, Limited | DETECTION OF FGFR2 |
| MX2017017172A (es) | 2015-06-22 | 2018-02-23 | Bayer Pharma AG | Conjugados de ligador-principio activo (adcs) y conjugados de ligador-profarmaco (apdcs) con grupos enzimaticamente escindibles. |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| RU2021107536A (ru) | 2015-11-23 | 2021-07-02 | Файв Прайм Терапьютикс, Инк. | Ингибиторы fgfr2 отдельно или в комбинации с иммуностимулирующими агентами в лечении рака |
| WO2017100642A1 (en) | 2015-12-11 | 2017-06-15 | Regeneron Pharmaceuticals, Inc. | Methods for reducing or preventing growth of tumors resistant to egfr and/or erbb3 blockade |
| SG11201808167VA (en) | 2016-03-24 | 2018-10-30 | Bayer Pharma AG | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
| JP7022707B2 (ja) | 2016-06-15 | 2022-02-18 | バイエル・ファルマ・アクティエンゲゼルシャフト | Ｋｓｐ阻害剤および抗ｃｄ１２３抗体を含む特異的抗体－薬物－コンジュゲート（ａｄｃ） |
| CN107513106A (zh) * | 2016-06-17 | 2017-12-26 | 艾托金生物医药（苏州）有限公司 | 抗FGFR2-IIIc单克隆抗体、杂交瘤细胞株和应用 |
| RU2019104730A (ru) * | 2016-07-29 | 2020-08-28 | Чугаи Сейяку Кабусики Кайся | Биспецифическое антитело, обладающее повышенной активностью, альтернативной функции кофактора fviii |
| US20190204326A1 (en) * | 2016-09-27 | 2019-07-04 | The University Of The Highlands And Islands | Antigen biomarkers |
| CA3047522A1 (en) | 2016-12-21 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Specific antibody drug conjugates (adcs) having ksp inhibitors |
| WO2018114578A1 (de) | 2016-12-21 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Binder-wirkstoff-konjugate (adcs) mit enzymatisch spaltbaren gruppen |
| CN110312533B (zh) | 2016-12-21 | 2023-11-03 | 拜耳公司 | 具有酶促可裂解的基团的细胞毒性活性剂的前药 |
| SG10202112636SA (en) | 2017-05-16 | 2021-12-30 | Five Prime Therapeutics Inc | Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment |
| JOP20190280A1 (ar) | 2017-06-02 | 2019-12-02 | Janssen Pharmaceutica Nv | مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية |
| MX2020002710A (es) | 2017-09-29 | 2020-07-20 | Chugai Pharmaceutical Co Ltd | Molecula de union al antigeno multiespecifica que tiene actividad de sustitucion de la funcion de cofactor del factor viii de coagulacion de sangre (fviii) y formulacion farmaceutica que contiene tal molecula como ingrediente activo. |
| WO2019246572A1 (en) * | 2018-06-22 | 2019-12-26 | Children's Medical Center Corporation | Compositions and methods for treating primary aldosteonism |
| MA53655A (fr) | 2018-09-21 | 2021-12-29 | Janssen Pharmaceutica Nv | Traitement du cholangiocarcinome |
| AU2020410863A1 (en) * | 2019-12-24 | 2022-06-23 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Novel anti-FGFR2b antibodies |
| JP2023528454A (ja) * | 2020-06-03 | 2023-07-04 | ザ・ブロード・インスティテュート・インコーポレイテッド | 線維芽細胞増殖因子受容体２に特異的に結合する二重パラトープアンタゴニスト抗体およびその使用方法 |
| US11866502B2 (en) | 2020-10-22 | 2024-01-09 | Regeneron Pharmaceuticals, Inc. | Anti-FGFR2 antibodies and methods of use thereof |
| WO2023113806A1 (en) | 2021-12-16 | 2023-06-22 | Affinia Therapeutics, Inc. | Recombinant aav for treatment of neural disease |
| WO2022221193A1 (en) | 2021-04-12 | 2022-10-20 | Affinia Therapeutics Inc. | Recombinant aav for treatment of neural disease |
| IL308404A (en) | 2021-04-27 | 2024-01-01 | Generation Bio Co | Non-viral DNA vectors expressing therapeutic antibodies and uses thereof |
| WO2023177655A1 (en) | 2022-03-14 | 2023-09-21 | Generation Bio Co. | Heterologous prime boost vaccine compositions and methods of use |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| ES2206447T3 (es) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
| EP0859841B1 (en) | 1995-08-18 | 2002-06-19 | MorphoSys AG | Protein/(poly)peptide libraries |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US20070248605A1 (en) * | 2003-12-19 | 2007-10-25 | Five Prime Therapetutics, Inc. | Fibroblast Growth Factor Receptors 1,2,3, and 4 as Targets for Therapeutic Intervention |
| US8101721B2 (en) | 2006-06-15 | 2012-01-24 | Fibron Ltd. | Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof |
| ES2523740T3 (es) * | 2008-11-07 | 2014-12-01 | Galaxy Biotech, Llc | Anticuerpos monoclonales para el receptor del factor de crecimiento de fibroblastos 2 |
| WO2010105426A1 (zh) | 2009-03-19 | 2010-09-23 | 华为技术有限公司 | 一种线性分组码编码的方法和装置 |
| MX2012013068A (es) * | 2010-05-11 | 2013-03-05 | Aveo Pharmaceuticals Inc | Anticuerpos anti - fgfr2. |
-
2012
- 2012-11-21 AR ARP120104379A patent/AR088941A1/es active Pending
- 2012-11-22 SG SG10201603880WA patent/SG10201603880WA/en unknown
- 2012-11-22 KR KR1020147016644A patent/KR20140102698A/ko not_active Application Discontinuation
- 2012-11-22 US US14/359,663 patent/US20140322220A1/en not_active Abandoned
- 2012-11-22 AU AU2012342474A patent/AU2012342474A1/en not_active Abandoned
- 2012-11-22 SG SG11201401973TA patent/SG11201401973TA/en unknown
- 2012-11-22 CN CN201280067865.9A patent/CN104066750B/zh not_active Expired - Fee Related
- 2012-11-22 WO PCT/EP2012/073325 patent/WO2013076186A1/en active Application Filing
- 2012-11-22 RU RU2014125143/10A patent/RU2014125143A/ru not_active Application Discontinuation
- 2012-11-22 CA CA2856325A patent/CA2856325A1/en not_active Abandoned
- 2012-11-22 MX MX2014005855A patent/MX2014005855A/es unknown
- 2012-11-22 EP EP12794685.3A patent/EP2782934A1/en not_active Withdrawn
- 2012-11-22 JP JP2014542825A patent/JP2015504434A/ja not_active Ceased
- 2012-11-22 BR BR112014012137A patent/BR112014012137A2/pt not_active IP Right Cessation
-
2014
- 2014-04-30 IL IL232399A patent/IL232399A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN104066750B (zh) | 2017-05-17 |
| US20140322220A1 (en) | 2014-10-30 |
| IL232399A0 (en) | 2014-06-30 |
| CN104066750A (zh) | 2014-09-24 |
| WO2013076186A1 (en) | 2013-05-30 |
| NZ624534A (en) | 2016-06-24 |
| AU2012342474A1 (en) | 2014-05-22 |
| SG10201603880WA (en) | 2016-07-28 |
| AR088941A1 (es) | 2014-07-16 |
| JP2015504434A (ja) | 2015-02-12 |
| EP2782934A1 (en) | 2014-10-01 |
| MX2014005855A (es) | 2014-07-30 |
| RU2014125143A (ru) | 2015-12-27 |
| CA2856325A1 (en) | 2013-05-30 |
| SG11201401973TA (en) | 2014-09-26 |
| KR20140102698A (ko) | 2014-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR23C1023I2 (fr) | Anticorps anti-il-36r | |
| IL281250A (en) | Anti-PHF-tau antibodies and uses thereof | |
| BR112014012137A2 (pt) | anticorpos anti-fgfr2 e suas utilizações | |
| CO6811812A2 (es) | Anticuerpo anti-b7-h3 | |
| DK2934584T3 (da) | Anti-gdf15-antistoffer | |
| BR112012030311A2 (pt) | anticorpo | |
| DK2785375T3 (da) | Anti-pd-l1-antistoffer og anvendelser deraf | |
| CO7071096A2 (es) | Anticuerpos anti-lgr5 e inmunoconjugados | |
| DK2850101T3 (da) | Anti-FcRn-antistoffer | |
| DK2914291T3 (da) | Anti-komplement-c1s-antistoffer og anvendelser deraf | |
| DK3275892T3 (da) | Præfusions-rsv-f-antigener | |
| DK3556774T3 (da) | Anti-CD40-antistoffer og anvendelser deraf | |
| BR112014009050A2 (pt) | pirrolbenzodiazepinas e conjugados destas | |
| BR112015002193A2 (pt) | anticorpos anti-etbr e imunoconjugados | |
| EP2756094A4 (en) | ANTI-B7-H4 ANTIBODIES AND USES THEREOF | |
| DK3467500T3 (da) | Cobinder-understøttede assayfremgangsmåder | |
| CR20140127A (es) | Anticuerpo anti-abtcr | |
| DK3381943T3 (da) | Anti-kit-antistoffer og anvendelser deraf | |
| BR112014002399A2 (pt) | conjunto | |
| DK2668210T3 (da) | Anti-kit antistoffer og anvendelser deraf | |
| BR112014025037A2 (pt) | anticorpo ou um fragmento funcional do mesmo, nucleotídeo, vetor recombinante, célula, métodos para a produção de um anticorpo ou fragmento funcional, para detecção ou ensaio de fgfr2 humano iiib, para a identificação de um indivíduo receptor de uma composição farmacêutica, e, para identificar e para produzir uma substância, forma modificada, composição, e, reagente | |
| CO6791565A2 (es) | Anticuerpos anti-notch1 | |
| DK3453723T3 (da) | Anti-ASIC1-antistoffer og anvendelser deraf | |
| DK3202789T3 (da) | Anti-vla-4-antistoffer | |
| DK2828292T3 (da) | Jcv-neutraliserende antistoffer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2494 DE 23-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |